Technology investment

Where is your AI investment losing value?

A CFO guide to Ghost Seat Software Bleed, the recurring loss hiding inside multi-year AI contracts.

The deployment dashboard says the rollout is complete. The invoice says you are fully committed. Neither tells you how many of those seats are actually used.

That gap between what you pay for and what your people adopt has a name.

The loss that never appears as a line item

Ghost Seat Software Bleed is the recurring financial loss that occurs when organisations continue paying for AI licences that are not creating business value. It rarely appears as a single budget overrun or unexpected expense. Instead, it compounds quietly, renewal after renewal, invoice after invoice, while implementation appears successful.

The problem is structural.

Licences are purchased uniformly. Organisational readiness never is.

Some departments are ready to adopt AI immediately, while others require different levels of capability, leadership support, or operational change before AI becomes part of everyday work. Yet licences are often deployed evenly across the organisation, regardless of those differences.

The result is that technology investment outpaces organisational readiness. Capital is committed before the organisation is ready to convert AI investment into measurable business value.

What it costs

Consider an organisation that commits to 500 AI licences at $50 per user per month. That represents an annual software investment of $300,000.

If only 300 employees actively use those licences, the remaining 200 licences still cost $120,000 every year without contributing meaningful value. Over a typical three-year agreement, that represents $360,000 committed to software capacity that the organisation is not yet using.

These figures are illustrative, but they reflect a commercial challenge many organisations encounter as AI investments scale.

The financial impact extends well beyond unused licences.

Every licence purchased before it is genuinely required ties up capital that could otherwise be invested in workforce capability, operational improvement, customer initiatives, or future AI investments. As software investment grows ahead of organisational readiness, costs increase while business value remains unrealised.

The executive question is therefore not simply: “How many licences have we purchased?”

It is: “How many licences are genuinely required today, and where will additional licences create measurable business value?”

Organisations that align licence investment with organisational readiness are more likely to reduce unnecessary expenditure, improve capital allocation, and realise greater business value from their AI investments.

The decision this informs

The executive decision is often framed as a procurement question: “Should we purchase another 500 AI licences?”

A more valuable question is: “Which departments are ready to convert additional AI access into measurable business value, and which will simply add to software overhead?”

That is a readiness decision, not a procurement decision. It can be answered before capital is committed.

The DRIVE™ Adaptability Diagnostic measures department-level readiness before AI investment decisions are made, enabling organisations to align licence procurement with organisational readiness rather than assumptions.

Before your next AI licence renewal or expansion, identify which departments are ready to convert additional AI access into measurable business value, and which are not.